BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCDA BioCardia

Pre-Mkt 11-13 07:52:01 EST

0.8260

-0.0957

-10.38%

盘前0.8563

+0.0303+3.67%

07:25 EST

High0.9499	Low0.6610	Vol296.62K
Open0.9499	D1 Closing0.9217	Amplitude31.34%
Mkt Cap12.50M	Tradable Cap10.01M	Total Shares15.14M
T/O237.76K	T/O Rate2.45%	Tradable Shares12.12M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BCDA","market":"US","secType":"STK","nameCN":"BioCardia","latestPrice":0.826,"timestamp":1794517200000,"preClose":0.9217,"halted":0,"volume":296616,"hourTrading":{"tag":"盘前","latestPrice":0.8563,"preClose":0.826,"latestTime":"07:25 EST","volume":800,"amount":685.04,"timestamp":1794572751951,"change":0.0303,"changeRate":0.036683,"amplitude":0},"delay":0,"changeRate":-0.10382987957035913,"floatShares":12117398,"shares":15138782,"eps":-0.73929,"marketStatus":"Pre-Mkt","change":-0.0957,"latestTime":"11-13 07:52:01 EST","open":0.9499,"high":0.9499,"low":0.661,"amount":237758.67992040003,"amplitude":0.313443,"askPrice":0.945,"askSize":1000,"bidPrice":0.7682,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-0.73929,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1794580200000},"marketStatusCode":1,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.826,"preHourTrading":{"tag":"盘前","latestPrice":0.8563,"preClose":0.826,"latestTime":"07:25 EST","volume":800,"amount":685.04,"timestamp":1794572751951,"change":0.0303,"changeRate":0.036683,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":0.85,"preClose":0.826,"latestTime":"19:56 EST","volume":8398,"amount":6930.9298,"timestamp":1794531379374,"change":0.024,"changeRate":0.029056,"amplitude":0.049516},"volumeRatio":2.8664145026892323,"impliedVol":0.046,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/BCDA","defaultTab":"news","newsList":[{"id":"2683546418","title":"BioCardia Inc Reports Results for the Quarter Ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2683546418","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683546418?lang=en_us&edition=fundamental","pubTime":"2026-11-13 07:41","pubTimestamp":1794526869,"startTime":"0","endTime":"0","summary":"BioCardia Inc reports results for the quarter ended September 30 - Earnings SummaryBioCardia IncBCDA.OQreported a quarterly adjusted loss of 12 cents per share for the quarter ended September 30, high","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nL5N46T361:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683510109","title":"BioCardia Q3 2026 Net Loss Widens 20% to $1.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2683510109","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683510109?lang=en_us&edition=fundamental","pubTime":"2026-11-13 05:30","pubTimestamp":1794519033,"startTime":"0","endTime":"0","summary":"BioCardia Q3 2026 net loss widens 20% to $1.8 millionBioCardia’s third-quarter 2026 net loss widened 20% year over year to $1.8 million.Research and development expenses rose 28% year over year to $1.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261112:nNDL1rswRH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683517073","title":"Press Release: BioCardia Reports Third Quarter 2026 Business Highlights and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2683517073","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683517073?lang=en_us&edition=fundamental","pubTime":"2026-11-13 05:19","pubTimestamp":1794518340,"startTime":"0","endTime":"0","summary":"process with Japan's Pharmaceuticals and Medical Devices Agency . concerning the application materials required to obtain regulatory. approval in Japan. Questions remaining to be addressed in advance of. and the U.S. FDA. We are working with partners to complete the electronic. trial master file, conduct good clinical practice audits, and structure. clinical research data in accordance with CDISC Standards, which support. data consistency, traceability, and regulatory compliance. We have. engaged a Designated Marketing Authorization Holder, or DMAH, as the. local regulatory representative required for foreign medical device and. pharmaceutical companies seeking to sell products in Japan without. establishing a local office. In Japan, the DMAH designation may be. -- BioCardia continues to actively enroll in the CardiAMP HF II trial. Four. clinical sites have enrolled in the study and are actively recruiting. patients.  Seven additional world class sites are being onboarded.-- Near term ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4099","BK4588","BCDA","TM","BK4555","BK4585","BK4232","LABU","R","BK9077","BK4022","03160","BK4604","BK4139","032820.KR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2683517434","title":"BioCardia Q3 EPS $(0.12) Beats $(0.13) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2683517434","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2683517434?lang=en_us&edition=fundamental","pubTime":"2026-11-13 05:12","pubTimestamp":1794517928,"startTime":"0","endTime":"0","summary":"BioCardia Q3 EPS $(0.12) Beats $(0.13) Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/quote/BCDA","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BioCardia Q3 EPS $(0.12) Beats $(0.13) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682341517","title":"BioCardia Inc Expected to Post a Loss of 13 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2682341517","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682341517?lang=en_us&edition=fundamental","pubTime":"2026-11-11 05:51","pubTimestamp":1794347466,"startTime":"0","endTime":"0","summary":"BioCardia Inc <BCDA.OQ> expected to post a loss of13cents a share - Earnings PreviewBioCardia IncBCDA.OQBCDA.Ois expected to  show no change in quarterly revenue when it reports  results on November 12 for the period ending September 30 2026LSEG's mean analyst estimate for BioCardia Inc is for a loss of 13 cents per share.The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for BioCardia Inc is $15.50, about 1,617.3% above its last closing price of $0.90This summary was machine generated November 10 at 21:51 GMT.  All figures in US dollars unless otherwise stated.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261110:nL5N46R2M2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2682040331","title":"BioCardia to Host Q3 2026 Financial Results and Corporate Update Conference Call on November 12, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2682040331","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2682040331?lang=en_us&edition=fundamental","pubTime":"2026-11-10 05:18","pubTimestamp":1794259080,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., Nov.  09, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ:BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/11/09/3399016/0/en/biocardia-to-host-q3-2026-financial-results-and-corporate-update-conference-call-on-november-12-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681890345","title":"BioCardia Inc Expected to Post a Loss of 13 Cents a Share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2681890345","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681890345?lang=en_us&edition=fundamental","pubTime":"2026-11-07 07:19","pubTimestamp":1794007145,"startTime":"0","endTime":"0","summary":"BioCardia Inc <BCDA.OQ> expected to post a loss of13cents a share - Earnings PreviewBioCardia IncBCDA.OQBCDA.Ois expected to  show no change in quarterly revenue when it reports  results on November 10  for the period ending September 30 2026LSEG's mean analyst estimate for BioCardia Inc is for a loss of 13 cents per share.The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 2 \"strong buy\" or \"buy,\" no \"hold\" and no \"sell\" or \"strong sell.\"The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for BioCardia Inc is $15.50, about 1,723.5% above its last closing price of $0.85This summary was machine generated November 6 at 23:19 GMT.  All figures in US dollars unless otherwise stated.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261106:nL5N46N2Q7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681545864","title":"Biocardia Completes Clinical Consultation Process with Japan's Pmda for Cardiamp Cell Therapy System","url":"https://stock-news.laohu8.com/highlight/detail?id=2681545864","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681545864?lang=en_us&edition=fundamental","pubTime":"2026-11-06 21:42","pubTimestamp":1793972546,"startTime":"0","endTime":"0","summary":"BRIEF-Biocardia Completes Clinical Consultation Process With Japan's Pmda For Cardiamp Cell Therapy SystemNov 6 (Reuters)-BioCardia IncBCDA.O:BIOCARDIA COMPLETES CLINICAL CONSULTATION PROCESS WITH JAP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261106:nFWN46N1J5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681610888","title":"BioCardia Advances CardiAMP Toward Japan Approval After Completing PMDA Consultations","url":"https://stock-news.laohu8.com/highlight/detail?id=2681610888","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681610888?lang=en_us&edition=fundamental","pubTime":"2026-11-06 21:31","pubTimestamp":1793971889,"startTime":"0","endTime":"0","summary":"BioCardia Advances CardiAMP Toward Japan Approval After Completing PMDA ConsultationsBioCardia completed consultations with Japan's PMDA on application materials for its CardiAMP cell therapy for isch","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261106:nNDL1qJFSB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681861240","title":"BioCardia Completes Clinical Consultation Process with Japan's Pmda for Cardiamp Cell Therapy System, Advancing Toward Submission of Marketing Approval Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2681861240","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681861240?lang=en_us&edition=fundamental","pubTime":"2026-11-06 21:30","pubTimestamp":1793971811,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261106:nFWN46N1J5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681686127","title":"BioCardia - Targets First Patient Treatment and Commercial Revenues in Japan in 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2681686127","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681686127?lang=en_us&edition=fundamental","pubTime":"2026-11-06 21:30","pubTimestamp":1793971811,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261106:nFWN46N1J5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677145286","title":"BioCardia President and CEO Peter Altman Reports Acquisition of $475 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2677145286","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2677145286?lang=en_us&edition=fundamental","pubTime":"2026-10-21 05:42","pubTimestamp":1792532576,"startTime":"0","endTime":"0","summary":"BioCardia President and CEO Peter Altman Reports Acquisition of $475 in Common SharesBioCardia President and CEO Peter Altman purchased 500 common shares at a reported weighted-average price of $0.95 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261020:nNDL5jjgm9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"BioCardia President and CEO Peter Altman Reports Acquisition of $475 in Common Shares","news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676068180","title":"BioCardia announces FDA acceptance of Helix pre-submission package","url":"https://stock-news.laohu8.com/highlight/detail?id=2676068180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676068180?lang=en_us&edition=fundamental","pubTime":"2026-10-19 21:41","pubTimestamp":1792417262,"startTime":"0","endTime":"0","summary":"BioCardia (BCDA) announced the FDA has accepted its pre-submission package for marketing clearance of its Helix catheter intended for therapeutic a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/biocardia-announces-fda-acceptance-of-helix-pre-submission-package-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/biocardia-announces-fda-acceptance-of-helix-pre-submission-package-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4139","BK4588","LABU","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676689515","title":"BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected This Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2676689515","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676689515?lang=en_us&edition=fundamental","pubTime":"2026-10-19 21:15","pubTimestamp":1792415700,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nTUA8NYDZC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676968964","title":"BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2676968964","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676968964?lang=en_us&edition=fundamental","pubTime":"2026-10-19 21:15","pubTimestamp":1792415700,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., Oct.  19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseas","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/10/19/3383509/0/en/biocardia-announces-fda-acceptance-of-de-novo-pre-submission-package-for-helix-catheter-marketing-clearance-fda-substantive-review-and-meeting-expected-this-quarter.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BCDA","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673013937","title":"BioCardia Outlines Design of CardiAMP HF II Heart Failure Trial at HFSA 2026 Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2673013937","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673013937?lang=en_us&edition=fundamental","pubTime":"2026-10-07 21:01","pubTimestamp":1791378069,"startTime":"0","endTime":"0","summary":"BioCardia outlines design of CardiAMP HF II heart failure trial at HFSA 2026 meetingBioCardia flagged an upcoming HFSA 2026 poster detailing the design of its CardiAMP HF II heart-failure trial.Result","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261007:nNDL8xKGvM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","SG9999014039.USD","BK4139","LU2210149790.SGD","BK4585","SG9999014021.USD","SG9999014005.SGD","LU0314104364.USD","SG9999014013.SGD","BK4112","IE00BN0W2W23.USD","BK4588","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","BCDA","IE00BQXX3C00.GBP","LU2095319765.USD","NDAQ","IE00BN0W2V16.EUR","IE00BQXX3D17.EUR","LU2210150020.SGD","IE00BQXX3F31.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672577467","title":"BioCardia Files Revised FDA De Novo Pre-Submission for Helix Catheter Clearance","url":"https://stock-news.laohu8.com/highlight/detail?id=2672577467","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672577467?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:15","pubTimestamp":1790860535,"startTime":"0","endTime":"0","summary":"BioCardia files revised FDA De Novo pre-submission for Helix catheter clearanceBioCardia filed a revised De Novo pre-submission with the FDA for marketing clearance of its Helix catheter for heart age","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nNDL4LqHyY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3F31.USD","LU2210150020.SGD","BCDA","SG9999014039.USD","IE00BGHQF748.EUR","IE00BKPKM429.USD","IE00BN0W2V16.EUR","IE00B3QW5Z07.USD","BK4585","BK4139","LU2210149790.SGD","SG9999014005.SGD","BK4112","IE00B64PRP62.GBP","BK4588","SG9999014021.USD","IE00BN0W2T93.GBP","LU2095319765.USD","IE00BN0W2W23.USD","IE00BQXX3C00.GBP","BCDF","IE00BQXX3D17.EUR","SG9999014013.SGD","LU0314104364.USD","NDAQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672792757","title":"BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter","url":"https://stock-news.laohu8.com/highlight/detail?id=2672792757","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672792757?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:15","pubTimestamp":1790860500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUA57W0PH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672757790","title":"BioCardia - FDA Targets Initial Review Within 15 Days and Feedback or Meeting Within 70 Days","url":"https://stock-news.laohu8.com/highlight/detail?id=2672757790","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672757790?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:15","pubTimestamp":1790860500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUA57W0PH:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCDA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2672718757","title":"BioCardia - FDA Raises no Concerns Regarding Helix Safety Data or Device Performance","url":"https://stock-news.laohu8.com/highlight/detail?id=2672718757","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2672718757?lang=en_us&edition=fundamental","pubTime":"2026-10-01 21:15","pubTimestamp":1790860500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261001:nTUA57W0PH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCDA"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biocardia.com","stockEarnings":[{"period":"1week","weight":-0.0719},{"period":"1month","weight":-0.1659},{"period":"3month","weight":-0.1517},{"period":"6month","weight":-0.1822},{"period":"1year","weight":-0.3646},{"period":"ytd","weight":-0.3392}],"compareEarnings":[{"period":"1week","weight":0.0329},{"period":"1month","weight":-0.0269},{"period":"3month","weight":-0.0248},{"period":"6month","weight":0.0243},{"period":"1year","weight":0.1079},{"period":"ytd","weight":0.1103}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.066663},{"month":2,"riseRate":0.5,"avgChangeRate":-0.017269},{"month":3,"riseRate":0.25,"avgChangeRate":-0.022375},{"month":4,"riseRate":0.375,"avgChangeRate":0.007226},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.09523},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.005776},{"month":7,"riseRate":0.444444,"avgChangeRate":-0.051846},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.048777},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.004864},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.060242},{"month":11,"riseRate":0.444444,"avgChangeRate":0.033337},{"month":12,"riseRate":0.375,"avgChangeRate":-0.012187}],"exchange":"NASDAQ","name":"BioCardia","nameEN":"BioCardia"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.53.0","shortVersion":"4.53.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioCardia(BCDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioCardia,BCDA,BioCardia股票,BioCardia股票老虎,BioCardia股票老虎国际,BioCardia行情,BioCardia股票行情,BioCardia股价,BioCardia股市,BioCardia股票价格,BioCardia股票交易,BioCardia股票购买,BioCardia股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioCardia(BCDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}